Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Abstract Myelofibrosis (MF) is characterized by splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, anemia, constitutional symptoms, and risk of secondary acute myeloid leukemia (sAML). The prognosis for sAML is very poor, with a median survival of less than 6 months, largely due to it...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-12-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-024-00616-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|